car-t-target
No description yet: the sentence for this tag has not been written. 8 records carry it: 8 targets.
8 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
BCMA TNFRSF17 BCMA is a survival receptor on plasma cells, and the target that made CAR-T and bispecifics work in multiple myeloma. | Multiple myeloma | none | t-cell-engager-target | ||
CD19 CD19 CD19 is a marker on B cells and B-cell cancers, and was the target of the first CAR-T therapies ever approved. | Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma, Chronic lymphocytic leukaemia | none | none | ||
CD22 CD22 CD22 is a B-cell surface protein and the docking site for the leukaemia ADC inotuzumab ozogamicin. | Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma | none | adc-target | ||
CD70 CD70 CD70 is a protein normally only on activated immune cells, but permanently switched on in kidney cancer and some leukaemias. | Renal cell carcinoma, Acute myeloid leukaemia | none | none | ||
Claudin 18.2 CLDN18 A tight-junction protein normally hidden in the stomach lining that becomes exposed in gastric and pancreatic cancers. | Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma | none | adc-target | ||
GD2 (disialoganglioside) GD2 (B4GALNT1 product) GD2 is a sugar-fat molecule on the surface of neuroblastoma cells (and some other childhood and adult tumours) with almost none on normal tissue except nerves, which is why anti-GD2 drugs cause pain. | Neuroblastoma, Sarcomas, Melanoma | none | antibody-target | ||
Glypican-3 GPC3 Glypican-3 is a fetal liver protein that reappears in liver cancer, giving CAR-T and bispecifics a clean target. | Hepatocellular carcinoma | none | none | ||
Mesothelin MSLN Mesothelin is a surface protein on mesothelioma, ovarian, and pancreatic cancers, targeted by ADCs, CAR-T, and T-cell engagers. | Mesothelioma, Pancreatic ductal adenocarcinoma, Ovarian cancer | none | adc-target |